Recently, TrialSite News reported on an Australian research team (Monash University & Peter Doherty Institute) uncovering the potential that ivermectin could potentially be used as a treatment against COVID-19. Recently, the U.S. Food and Drug Administration (FDA) had to warn people not to self-mediate with ivermectin-based products intended for animals, thinking they can be used for ivermectin intended for humans.
The Work in Australia
TrialSite News reported that a collaborative effort involving Monash University’s Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity at Royal Melbourne Hospital published the results revealing that ivermectin, an approved anti-parasitic drug available worldwide, may actually treat against SARS-CoV-2 when applied to an infected cell culture. Of course, this test was done in a lab a not on real people so there is much work to do to evaluate these findings.
Remind People not to take Drugs not Approved!
In the meantime, the FDA’s Center for Veterinary Medicine became aware lately of increased public visibility of the antiparasitic drug after the research announcement. Hence, the FDA must offer the following recommendations:
- Ivermectin is not approved for COVID-19 treatments. People should not take any form of the drug unless it has been prescribed by a licensed health care provider and is obtained via a legal and legitimate source
- People should never take drugs that are for animals! They can cause serious harm to people.
- The drug tablets approved for use in humans for treatment of some parasitic worms (intestinal strongyloidiasis and onchocerciasis) and ivermectin topical formulations are approved for human use by prescription only for the treatment of external parasites such as headlice and for skin conditions, such as rocea.
Call to Action: Sign up for the TrialSite News daily newsletter for updates on Ivermectin research updates in the context of COVID-19; and you are part of our rapidly growing TrialSite Network. This growing global clinical research social network affords you access to not only ongoing updates but also Q&A service and new website functions in development.